Breast Surgery, Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, NY 14263, USA.
Department of Surgery, Jacobs School of Medicine and Biomedical Sciences, State University of New York, Buffalo, New York, NY 14263, USA.
Int J Mol Sci. 2020 Oct 30;21(21):8127. doi: 10.3390/ijms21218127.
is one of the most studied oncogenes that is known to promote cell proliferation. We utilized MYC targets v1 and MYC targets v2 scores of gene set variation analysis and hypothesized that these scores correlate with tumor aggressiveness and survival outcomes. We examined a total of 3109 breast cancer patients from TCGA, METABRIC, and GSE124647 cohorts. In each cohort, the patients were divided into high- and low-score groups using the upper third value as the cut off. As expected, higher scores were related to increased cell proliferation and worse clinical and pathologic features. High MYC targets scores were associated with worse survival, specifically in primary ER-positive breast cancer, consistently in both TCGA and METABRIC cohorts. In ER-positive breast cancer, high MYC targets v1, but not v2 score, was associated with high mutation load, and high MYC targets v1 and v2 scores were both associated with increased infiltration of pro- and anti-cancerous immune cells. We found that high MYC scores were associated with worse survival in metastatic breast cancer. Our findings show that the MYC targets v1 and v2 scores are associated with tumor aggressiveness and poor prognosis in ER-positive primary tumors, as well as in metastatic breast cancer.
是研究最多的致癌基因之一，已知可促进细胞增殖。我们利用基因集变异分析的 MYC 靶标 v1 和 MYC 靶标 v2 评分，并假设这些评分与肿瘤侵袭性和生存结果相关。我们共检查了来自 TCGA、METABRIC 和 GSE124647 队列的 3109 名乳腺癌患者。在每个队列中，我们使用上三分之一的值作为截止值将患者分为高分和低分组。正如预期的那样，更高的分数与增加的细胞增殖和更差的临床和病理特征相关。高 MYC 靶标评分与较差的生存相关，特别是在原发性 ER 阳性乳腺癌中，在 TCGA 和 METABRIC 队列中均一致。在 ER 阳性乳腺癌中，高 MYC 靶标 v1 评分而不是 v2 评分与高突变负荷相关，高 MYC 靶标 v1 和 v2 评分均与促进和抗癌免疫细胞的浸润增加相关。我们发现高 MYC 评分与转移性乳腺癌的生存率较差相关。我们的研究结果表明，MYC 靶标 v1 和 v2 评分与 ER 阳性原发性肿瘤的侵袭性和不良预后以及转移性乳腺癌相关。
Zotero 插件
